Qiang Wang

Assistant Professor

350 Shushanhu Road, Hefei, Anhui, 230031, P.R. China

Tel:+86-551-65593617

Email: wq2013@hmfl.ac.cn

Work and study experience

20015/09-present, Assist. Prof., Medicinal chemistry, High Magnetic Field Laboratory, CAS

20013/06-2015/08, PostDoctor, Medicinal chemistry, High Magnetic Field Laboratory, CAS

2008/09 –2013/06, Organic Chemistry, Doctor, USTC.

2004/09 –2008/06, Biology Science, bachelor, Huanggang Normal University.

 

Papers and patents

  1. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*,Jing Liu*. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2016, DOI: 10.1021/acs.jmedchem.6b01290.
  2. Feiyang Liu#, Beilei Wang#, Qiang Wang#, Ziping Qi#, Cheng Chen#, Lu-Lu Kong, Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun, Zhimin Zhai, Jing Liu*, Qingsong Liu*. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Oncotarget 2016, 7(29): 45562-45574.
  3. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Ziping Qi, Cheng Chen, Jing Liu*, Qingsong Liu*. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59(8): 3964.
  4. Ping Hu#, Xinghui Wang, Baiqun Zhang, Shuai Zhang, Qiang Wang* and Zhiyong Wang*, Fluorescence polarization applied in evaluating the inhibitory potency of small molecules towards PCAF BRD/Tat Ack-50 association, ChemMedChem 2014, 9: 928.
  5. Qiang Wang, Ruirui Wang, Baiqun Zhang, Shuai Zhang, Yongtang Zheng, Zhiyong Wang*. Small organic molecules targeting PCAF bromodomain as potent inhibitors of HIV-1 replication, Med. Chem. Commun. 2013, 4(4): 737-740.
  6. Qiang Wang, Shuai Zhang, Fengfeng Guo, ZhiYong Wang*. Natural α-amino acids applied in the synthesis of imidazo[1,5-a]N-heterocycles under mild conditions. J. Org. Chem. 2012, 77(24): 11161.
  7. Qiang Wang, ChangFeng Wan, Yang Gu, JinTang Zhang, LingFeng Gao, ZhiYong Wang*, Metal-free decarboxylative cyclization from natural α-amino acids to construct pyridine derivatives, Green Chem. 2011, 13(3): 578-581.
  8. 中国专利：一种化合物及其制备和应用，汪志勇, 王强, 姚雪彪, 郑永唐, 郑媛。专利号：CN 102952069
  9. 中国专利：一种新型结构的激酶抑制剂，刘青松，刘静，王强，刘飞扬，王蓓蕾，王傲莉，王文超，胡晨，陈程，赵铮，吴宏，王黎。专利受理号：201410757626.7
  10. 发明名称：一种新型的PDGFR激酶抑制剂及其用途，发明人： 刘青松，刘静， 王强, 刘飞扬，亓爽，王蓓蕾，王文超，王傲莉，王伟，陈程，刘晓川，蒋宗儒，胡祯全，任涛，王黎。专利受理号：201610811854.7
  11. 发明名称：一种选择性的C-KIT激酶抑制剂，发明人： 刘青松，刘静，王强，王蓓蕾，刘飞扬，亓爽，齐紫平，邹凤鸣，陈程，王文超，胡晨，刘晓川，王伟，王傲莉，王黎，胡祯全，任涛。专利受理号：2201610210424.X

Foundation

  1. 第55批中国博士后科学基金面上二等资助，针对胃肠间质瘤有效靶点C-KIT激酶的不可逆抑制剂研究、2014M551826、2014/05-2016/05、已结题，主持。
  2. 国家自然科学青年基金、针对血小板衍生生长因子受体PDGFRα激酶的高选择性高活性抑制剂发现研究、81602973、2017/01-2019/12、在研、主持。
  3. 安徽省自然科学青年基金、针对血小板衍生生长因子受体PDGFRα激酶的高选择性高活性抑制剂发现研究、1708085QH197、2017/01-2019/12、在研、主持。